Table 1.

5HPP-33 showed inhibition of cell proliferation of breast, prostate, ovarian, colon, bladder and lymphoma cancer cells

Cell type5HPP-33 [IC50 (μmol/L)]Thalidomide (μmol/L)Paclitaxel (μmol/L)
MCF-76.2 ± 0.4>3000.031 ± 0.0005
MDA-MB-2315.2 ± 0.3>300Not tested
HT-295.1 ± 1.4>300Not tested
TCCSUP6.5 ± 1.0>300Not tested
LNCaP1.7 ± 0.2>300Not tested
DU-1455.7 ± 0.2>3000.024 ± 0.001
PC-38.3 ± 0.8>3000.017 ± 0.004
1A92.1 ± 0.1>300Not tested
Hs Sultan11.1 ± 1.9>300Not tested
  • NOTE: 5HPP-33 showed inhibition of cell proliferation of both estrogen-dependent (MCF-7) and estrogen-independent (MDA-MB-231) breast cancer cells, colon cancer cells (HT-29), bladder cancer cells (TCCSUP), androgen-dependent (LNCaP) and androgen-independent prostate cancer cells (DU-145 and PC-3), ovarian carcinoma cells (1A9), and Burkitt's lymphoma (Hs Sultan). Cells (1,000 per well) were treated with varying concentration of 5HPP-33 and cell-associated protein was determined using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt assay. IC50s represent the means of three experiments in triplicate.